Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
Open accessAbstract
Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered IDH1 and IDH2 mutations in 34 of 326 (10%) intrahepatic cholangiocarcinomas. Tumor with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3 lysine 79 (H3K79). Mutations in IDH1 or IDH2 were associated with longer overall survival (P=0.028) and were independently associated with a longer time to tumor recurrence after intrahepatic cholangiocarcinoma resection in multivariate analysis (P=0.021). IDH1 and IDH2 mutations were significantly associated with increased levels of p53 in intrahepatic cholangiocarcinomas, but no mutations in the p53 gene were found, suggesting that mutations in IDH1 and IDH2 may cause a stress that leads to p53 activation. We identified 2309 genes that were significantly hypermethylated in 19 cholangiocarcinomas with mutations in IDH1 or IDH2, compared with cholangiocarcinomas without these mutations. Hypermethylated CpG sites were significantly enriched in CpG shores and upstream of transcription start sites, suggesting a global regulation of transcriptional potential. Half of the hypermethylated genes overlapped with DNA hypermethylation in IDH1-mutant gliobastomas, suggesting the existence of a common set of genes whose expression may be affected by mutations in IDH1 or IDH2 in different types of tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD8+ T cells are highly dependent on activation of HIF-1α and glycolysis, which mediates trafficking into hypoxic tumour environments and inflamed tissue.
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · see citing works
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · see citing works
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515 · see citing works
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451 · see citing works
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works
Self-citationTet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776 · see citing works
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works
Ito, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,542 · see citing works
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,506 · see citing works
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · see citing works
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235 · see citing works
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · see citing works
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Bisceglie, A. M. D., Bruix, J., Kramer, B. S., Lencioni, R. A., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M. T., Talwalkar, J. A., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,648 · see citing works
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,422 · see citing works
Self-citationTet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339 · see citing works
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226 · see citing works
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143 · see citing works
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130 · see citing works
Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · see citing works
Self-citationIDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · see citing works
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · see citing works
Marcucci, G., Maharry, K. S., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763 · see citing works
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728 · see citing works
Blechacz, B. R. A., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22310 · Cited by 698 · see citing works
Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., Barbera, A. J., Zheng, L., Zhang, H., Huang, S., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.005 · Cited by 634 · see citing works
DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing
Brenet, F. A., Moh, M., Funk, P., Feierstein, E., Viale, A. J., Socci, N. D., & Scandura, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014524 · Cited by 627 · see citing works
Genome-scale analysis of aberrant DNA methylation in colorectal cancerPreprint
Hinoue, T., Weisenberger, D. J., Lange, C., Shen, H., Byun, H., Van, D., Malik, S., Pan, F., Noushmehr, H., van, C., et al. (2011) · Genome Research · doi:10.1101/gr.117523.110 · Cited by 604 · see citing works
Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559 · see citing works
Emerging insights into the molecular and cellular basis of glioblastomaPreprint
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 559 · see citing works
Andersen, J. B., Spee, B., Blechacz, B. R. A., Avital, I., Komuta, M., Barbour, A. P., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 551 · see citing works
Self-citationOllier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
Amary, M. F., Damato, S., Halai, D., Eskandarpour, M., Berisha, F., Bonar, F., McCarthy, S., Fantin, V. R., Straley, K. S., Lobo, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.994 · Cited by 428 · see citing works
Abdel-Wahab, O. I., Manshouri, T., Patel, J. L., Harris, K., Yao, J., Hedvat, C. V., Heguy, A., Bueso-Ramos, C., Kantarjian, H. M., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 325 · see citing works
Human Hepatic Stem Cell and Maturational Liver Lineage Biology Δ
Turner, R., Lozoya, O. A., Wang, Y., Cardinale, V., Gaudio, E., Alpini, G. D., Mendel, G., Wauthier, E., Barbier, C., Alvaro, D., et al. (2011) · Hepatology · doi:10.1002/hep.24157 · Cited by 316 · see citing works
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang, F., Turcan, Ş., Rimner, A., Kaufman, A., Giri, D. D., Morris, L. G. T., Shen, R., Seshan, V., Mo, Q., Heguy, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001875 · Cited by 267 · see citing works
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Fritcher, E. G. B., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 243 · see citing works
Self-citationNagasaka, T., Sasamoto, H., Notohara, K., Cullings, H. M., Takeda, M., Kimura, K., Kambara, T., MacPhee, D. G., Young, J. P., Leggett, B., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.154 · Cited by 215 · see citing works
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 210 · see citing works
The biliary tree—a reservoir of multipotent stem cells
Cardinale, V., Wang, Y.-F., Carpino, G., Mendel, G. L., Alpini, G., Gaudio, E., Reid, L., & Alvaro, D. (2012) · Nature Reviews Gastroenterology &Hepatology · doi:10.1038/nrgastro.2012.23 · Cited by 206 · see citing works
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 129 · see citing works
Yang, B., Zhong, C., Peng, Y., Lai, Z., & Ding, J. (2010) · Cell Research · doi:10.1038/cr.2010.145 · Cited by 118 · see citing works
Andersen, J. B., Factor, V. M., Marquardt, J. U., Raggi, C., Lee, Y.-H., Seo, D., Conner, E. A., & Thorgeirsson, S. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001338 · Cited by 95 · see citing works
Self-citationБей, Yang, Chen, Zhong, Yingjie, ......................................................, P., Zheng, Lai, Jianping, & Ding (2010) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 67 · see citing works
Aishima, S.-I., Kuroda, Y., Nishihara, Y., Taguchi, K., Taketomi, A., Maehara, Y., & Tsuneyoshi, M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02414.x · Cited by 54 · see citing works
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,831 · see citing works
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J. A., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J., Patel, T. C., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,508 · see citing works
Bañales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,382 · see citing works
Self-citationPathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,311 · see citing works
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S., & Llovet, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,051 · see citing works
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,139 · see citing works
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014 · see citing works
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 972 · see citing works
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 787 · see citing works
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 689 · see citing works
Self-citationNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, Á., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626 · see citing works
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 616 · see citing works
Self-citationSulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 556 · see citing works
Self-citationChan-on, W., Nairismägi, M., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 495 · see citing works
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornellà, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460 · see citing works
IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 459 · see citing works
Self-citationExtreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433 · see citing works
Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Rand, J. V., Jones, D., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 453 · see citing works
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452 · see citing works
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S.-C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 430 · see citing works
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J. A., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 405 · see citing works
Coupling Krebs cycle metabolites to signalling in immunity and cancer
Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398 · see citing works
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 402 · see citing works
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367 · see citing works
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T. J., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B. F., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 352 · see citing works
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochín, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 350 · see citing works
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K. S., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 341 · see citing works
Kickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., von Deimling, A., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 314 · see citing works
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4017 · Cited by 300 · see citing works
Self-citationGrassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280 · see citing works
Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
McCoach, C. E., Le, A. T., Gowan, K., Jones, K., Schubert, L., Doak, A. E., Estrada‐Bernal, A., Davies, K. D., Merrick, D. T., Bunn, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2452 · Cited by 250 · see citing works
Metabolic rearrangements in primary liver cancers: cause and consequences
Satriano, L., Lewińska, M., Rodrigues, P. M., Bañales, J. M., & Andersen, J. B. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0217-8 · Cited by 241 · see citing works
Self-citationMetabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242 · see citing works
Self-citationWild-type and mutated IDH1/2 enzymes and therapy responses
Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 243 · see citing works
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Moeini, A., Sia, D., Bardeesy, N. M., Mazzaferro, V., & Llovet, J. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3296 · Cited by 241 · see citing works
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.008 · Cited by 239 · see citing works
Self-citationLi, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244 · see citing works
Self-citationThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 234 · see citing works
Lowery, M. A., Burris, H. A., Jankú, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 223 · see citing works
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 209 · see citing works
Exploration of liver cancer genomes
Shibata, T., & Aburatani, H. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.6 · Cited by 197 · see citing works
CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 191 · see citing works
The CpG Island Methylator Phenotype: What's in a Name?
Hughes, L., Melotte, V., Schrijver, J. M. D., de Maat, M., Smit, V. T. H. B. M., Bovée, J. V. M. G., French, P. J., van den Brandt, P. A., Schouten, L. J., Meyer, T. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4306 · Cited by 182 · see citing works
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 181 · see citing works
Emerging molecular therapeutic targets for cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.026 · Cited by 180 · see citing works
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhäuser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 178 · see citing works
Metabolic reprogramming in cholangiocarcinoma
Raggi, C., Taddei, M. L., Rae, C. J., Braconi, C., & Marra, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.038 · Cited by 177 · see citing works
Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance
Noch, E., Ramakrishna, R. R., & Magge, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.022 · Cited by 174 · see citing works
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Boerner, T., Drill, E. N., Pak, L. M., Nguyen, B., Sigel, C., Doussot, A., Shin, P. J., Goldman, D. A., Gönen, M., Allen, P. J., et al. (2021) · Hepatology · doi:10.1002/hep.31829 · Cited by 170 · see citing works
Mutant IDH1 and thrombosis in gliomas
Unruh, D. J., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1620-7 · Cited by 173 · see citing works
Self-citationMeta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2
Guilhamon, P., Eskandarpour, M., Halai, D., Wilson, G. A., Feber, A., Teschendorff, A. E., Gómez, V., Hergovich, A., Tirabosco, R., Amary, F. M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3166 · Cited by 169 · see citing works
Lamarca, Á., Ross, P. J., Wasan, H. S., Hubner, R. A., McNamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J. A., & Valle, J. W. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz071 · Cited by 162 · see citing works
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160 · see citing works
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 156 · see citing works
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 150 · see citing works
Radioprotection of <i>IDH1</i> -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148 · see citing works
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 145 · see citing works
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138 · see citing works
Role of Hepatocyte Nuclear Factor 4α (HNF4α) in Cell Proliferation and Cancer
Walesky, C. M., & Apte, U. M. (2015) · Gene Expression · doi:10.3727/105221615x14181438356292 · Cited by 138 · see citing works
Youssef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 140 · see citing works
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 138 · see citing works
Self-citationAkita, M., Fujikura, K., Ajiki, T., Fukumoto, T., Otani, K., Azuma, T., Itoh, T., Ku, Y., & Zen, Y. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.22 · Cited by 134 · see citing works
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 134 · see citing works
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Macı́as, R. I. R., Kornek, M., Rodrigues, P. M., Paiva, N. A., Castro, R. E., Urban, S. K., Pereira, S. P., Cadamuro, M., Rupp, C., Loosen, S. H., et al. (2019) · Liver International · doi:10.1111/liv.14090 · Cited by 131 · see citing works
Metabolic reprogramming and its clinical implication for liver cancer
Yang, F., Hilakivi-Clarke, L. A., Shaha, A., Wang, Y., Wang, X., Deng, Y., Lai, J., & Kang, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000005 · Cited by 133 · see citing works
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Ilyas, S. I., Borad, M. J., Patel, T. C., & Gores, G. J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394144 · Cited by 123 · see citing works
Squadroni, M., Tondulli, L., Gatta, G., Mosconi, S., Beretta, G. D., & Labianca, R. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.012 · Cited by 121 · see citing works
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 120 · see citing works
Self-citationJanin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 121 · see citing works
Diverse modes of genomic alteration in hepatocellular carcinoma
Jhunjhunwala, S., Jiang, Z., Stawiski, E. W., Gnad, F., Liu, J., Mayba, O., Du, P., Diao, J., Johnson, S., Wong, K., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0436-9 · Cited by 118 · see citing works
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
Jain, A., Kwong, L. N., & Javle, M. M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0432-2 · Cited by 119 · see citing works
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120 · see citing works
Krasinskas, A. M. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.02.005 · Cited by 119 · see citing works
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma
Goeppert, B. F., Tóth, R., Singer, S., Albrecht, T., Lipka, D. B., Lutsik, P., Brocks, D., Baehr, M., Muecke, O., Assenov, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30493 · Cited by 112 · see citing works
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 112 · see citing works
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis
Rahnemai‐Azar, A. A., Weisbrod, A. B., Dillhoff, M. E., Schmidt, C. R., & Pawlik, T. M. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2016.12.009 · Cited by 110 · see citing works
Wang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109 · see citing works
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Chong, D. Q., & Zhu, A. X. (2016) · Oncotarget · doi:10.18632/oncotarget.8775 · Cited by 109 · see citing works
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 110 · see citing works
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma
Macı́as, R. I. R., Bañales, J. M., Sangro, B., Muntané, J., Avila, M. A., Lozano, E., Perugorria, M. J., Ruiz, F. J. P., Bujanda, L., & Marı́n, J. J. G. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.002 · Cited by 106 · see citing works
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 104 · see citing works
Schlitter, A. M., Jang, K., Klöppel, G., Saka, B., Hong, S., Choi, H., Offerhaus, G. J. A., Hruban, R. H., Zen, Y., Konukiewitz, B., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.61 · Cited by 103 · see citing works
Suijker, J., Oosting, J., Koornneef, A., Struys, E. A., Salomons, G. S., Schaap, F. G., Waaijer, C. J. F., Wijers‐Koster, P. M., Bruijn, I. H. B., Haazen, L. C. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3723 · Cited by 100 · see citing works
Ferrone, C. R., Ting, D. T., Shahid, M., Konstantinidis, I. T., Sabbatino, F., Goyal, L., Rice-Stitt, T. L., Mubeen, A., Arora, K. S., Bardeesey, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4247-8 · Cited by 101 · see citing works
The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
Wang, T., Liang, J.-Y., Zhang, C., Xiong, Y., Guan, K., & Yuan, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1984-4 · Cited by 104 · see citing works
Self-citationRuzzenente, A., Fassan, M., Conci, S., Simbolo, M., Lawlor, R. T., Pedrazzani, C., Capelli, P., D’Onofrio, M., Iacono, C., Scarpa, A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5046-6 · Cited by 99 · see citing works
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
Liu, A., Hou, C., Chen, H., Zong, X., & Zong, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00016 · Cited by 99 · see citing works
Progress and prospects of biomarkers in primary liver cancer (Review).
Gao, Y.-X., Yang, T.-W., Yin, J., Yang, P.-X., Kou, B.-X., Chai, M., Liu, X.-N., & Chen, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5035 · Cited by 87 · see citing works
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 95 · see citing works
Evolution of the Experimental Models of Cholangiocarcinoma
Massa, A., Varamo, C., Vita, F., Tavolari, S., Neia, C. P., Brandi, G., Rizzo, A., Cavalloni, G., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12082308 · Cited by 95 · see citing works
Ma, B., Meng, H., Tian, Y., Wang, Y., Song, T., Zhang, T., Wu, Q., Cui, Y., Li, H., Zhang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06804-6 · Cited by 94 · see citing works
DNA Damage, DNA Repair and Cancer
Bernstein, C., Anil, R., Nfonsam, V. N., & Bernstei, H. (2013) · InTech eBooks · doi:10.5772/53919 · Cited by 94 · see citing works
Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T. L., Tan, J. C., Parekh, V., Benson, D. G., Crossman, D. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1727 · Cited by 89 · see citing works
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 87 · see citing works
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 85 · see citing works
Animal models of cholangiocarcinoma
Loeuillard, E. J., Fischbach, S. R., Gores, G. J., & Ilyas, S. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.026 · Cited by 82 · see citing works
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 85 · see citing works
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
Wang, H., Tang, K., Liang, T., Zhang, W., Li, J.-Y., Wang, W., Hu, H., Li, M., Wang, H., He, X.-Z., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0362-7 · Cited by 80 · see citing works
Self-citationMetabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 73 · see citing works
Fong, Z. V., Brownlee, S. A., Qadan, M., & Tanabe, K. K. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09671-y · Cited by 72 · see citing works
- Authors
- Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., Auman, J. T., Hoskins, J. M., Misher, A. D., Moser, C. D., Yourstone, S. M., Kim, J. W., Cibulskis, K., Getz, G., Hunt, H. V., Thorgeirsson, S. S., Roberts, L. R., Ye, D., Guan, K.-L., Xiong, Y., Qin, L.-X., & Chiang, D. Y.
- Affiliations
- Fudan University (CN)
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- Mayo Clinic (US)
- Atrium Health Wake Forest Baptist (US)
- Broad Institute (US)
- Corresponding author
- Xiong, Y
- Qin, L-X
- Chiang, D Y
- ORCID
- Venue
- Oncogene
- Published
- 2012-07-23
- Volume
- 32
- Issue
- 25
- Pages
- 3091-3100
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC3500578
- OpenAlex
- W2018041848
- Cited by
- 399
- References
- 48
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 26 · 2023: 22 · 2022: 19 · 2021: 38 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 38 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 22 · 2012: 3
- FWCI
- 29.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Fudan University
- National Institutes of Health (5r01ca149569-05)
- National Human Genome Research Institute (R01HG006272)
- National Cancer Institute (R01-CA149569, R01CA163834)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Keywords
- IDH mutation, IDH1, IDH2, intrahepatic cholangiocarcinoma, DNA hypermethylation, 5-hydroxymethylcytosine, 5-methylcytosine, p53 activation, overall survival, tumor recurrence, glioblastoma, transcriptional regulation, tumor resection
- MeSH terms
- Base Sequence, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Brain Neoplasms, Glioblastoma, Histones, Humans, Isocitrate Dehydrogenase, Liver Neoplasms, Mutation, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, Sequence Analysis, DNA, Cholangiocarcinoma, CpG Islands, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
